Tesamorelin Dosing Protocol: 5 mg Vial — Daily Dosing Schedule & Supplies
Tesamorelin FDA-approved GHRH analogue dosing guide for the 5 mg vial, based on the Egrifta SV 2 mg/day protocol for visceral fat reduction.
Quickstart highlights
Tesamorelin (TH9507) is a stabilized GHRH analogue where the native GHRH is conjugated to trans-3-hexenoic acid, improving stability against DPP-IV cleavage.
Concentration: 2 mg/mL (5 mg vial + 2.5 mL bacteriostatic water).
At 2 mg/mL: 1 mg = 50 units, 2 mg = 100 units (FDA-approved Egrifta SV daily dose).
Falutz et al. Phase 3: 2 mg/day reduced visceral adipose tissue by 15.2% at 26 weeks.
One 5 mg vial provides 2.5 days at 2 mg/day — approximately 3 vials per week needed.
Refrigerate; use within 28 days.
Dosing table
For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.
1-4
1000
50
Once daily
1 mg — 50 units; starting half-dose to assess tolerability; one 5 mg vial provides 5 daily doses
5-26
2000
100
2 mg — 100 units (FDA-approved Egrifta SV dose); one 5 mg vial provides 2.5 daily doses — approximately 2 vials per week at 2 mg/day
Your free Tesamorelin tracker
Dose reminders
Injection logging
Cycle progress
Reconstitution steps
Draw 2.5 mL bacteriostatic water; inject slowly down the vial wall.
Swirl gently until lyophilized powder dissolves completely; do not shake.
Final concentration: 2 mg/mL (5 mg / 2.5 mL). At 2 mg/mL: 2 mg = 100 units on a U-100 syringe.
Label with date; refrigerate at 2–8 °C. Use within 28 days. One 5 mg vial provides 2.5 days at 2 mg/day.
Supplies needed
4-week plan
6 vials
28 syringes
15 mL bac water
28 alcohol swabs
12-week plan
20 vials
84 syringes
50 mL bac water
84 alcohol swabs
Protocol overview & cycle notes
Reduce visceral adipose tissue through the FDA-approved 2 mg/day tesamorelin GHRH analogue protocol, with the 5 mg vial covering 2.5 days of maintenance dosing at once-daily injection.
Cycle length: 26 weeks on.
Off-cycle: 8 weeks off; tesamorelin is typically used in long cycles (26 weeks per clinical trial protocols).
Storage & handling
Injection & tracking tips
Inject subcutaneously in the abdomen (not into scar tissue or navel) once daily at the same time each day.
Tesamorelin is FDA-approved; the Egrifta SV formulation is 2 mg once daily for HIV-associated lipodystrophy. The same dose is used in off-label body composition protocols.
Rotate within a quadrant of the abdomen daily to minimize local reactions.
Tracking
Logging helps you and your provider spot patterns and adjust dose or timing.
Measure waist circumference and visceral fat (via DEXA or CT if available) at baseline, 12 weeks, and 26 weeks.
Track IGF-1 every 8 weeks — tesamorelin raises IGF-1 significantly; target upper-normal range for age.
Monitor fasting glucose monthly — GH elevation from tesamorelin can impair insulin sensitivity.
How this works & references
Sources
Metabolic effects of a growth hormone-releasing factor in patients with HIV. Falutz J et al. — N Engl J Med — 2007
FDA — Egrifta SV (tesamorelin) Prescribing Information
Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. González-Sales M et al. — Clin Pharmacokinet — 2015
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Falutz J et al. — J Acquir Immune Defic Syndr — 2010
Frequently asked questions
Related protocols
KLOW Blend Dosing Protocol — BPC-157, TB-500, KPV & GHK-Cu Guide
KLOW peptide blend (BPC-157 + TB-500 + KPV + GHK-Cu) dosing guide for tissue repair, anti-inflammatory support, and extracellular matrix remodeling — the GLOW blend plus KPV.
GLOW Blend Dosing Protocol — BPC-157, TB-500 & GHK-Cu Skin & Repair Guide
GLOW peptide blend (BPC-157 + TB-500 + GHK-Cu) dosing guide for tissue repair, angiogenesis, and collagen and connective-tissue remodeling.
Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide
Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.
Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide
Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.
This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.
Need help?